

*or innovative solutions in prevention, cure and care for the*

<Notes to Editor>

1. Six candidate compounds and target indications

	<b>Quintiles Collaboration</b>	<b>Eisai In-house Development</b>
eribulin mesylate	NSCLC (combo) Ph <sup>*</sup> -Ib/II Bladder (combo) Ph-Ib/II	Breast (mono) Ph-III Prostate (mono) Ph-II